• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=28881731; PubMed=30551515).
  

CLPUB00681
Berezhnoy A.E., Zakeyeva I.R., Kibardin A.V., Chernysheva A.D., Moiseyenko V.M., Danilov A.O., Demidov L.V., Baryshnikov A.Y., Gnuchev N.V., Georgiev G.P., Larin S.S.
Analysis of HLA-E expression in human melanoma cells.
Ross. Bioterap. Zh. 5:66-71(2006)

Patent=RU2287577
Mikhailova I.N., Baryshnikov A.Y., Morozova L.F., Burova O.S., Demidov L.V., Lukashina M.I., Larin S.S., Georgiev G.P., Vorozhtsov G.N., Gnuchev N.V.
Human melanoma cellular line mel IL used in preparing antitumor vaccine.
Patent number RU2287577, 20-Nov-2006

PubMed=18781128; DOI=10.1097/CMR.0b013e32830e391d
Mikhailova I.N., Kovalevsky D.A., Morozova L.F., Golubeva V.A., Cheremushkin E.A., Lukashina M.I., Voronina E.S., Burova O.S., Utyashev I.A., Kiselev S.L., Demidov L.V., Beabealashvilli R.S., Baryshnikov A.Y.
Cancer/testis genes expression in human melanoma cell lines.
Melanoma Res. 18:303-313(2008)

CLPUB00680
Mikhailova I.N., Baryshnikov A.Y., Morozova L.F., Burova O.S., Shubina I.Z., Kovalevsky D.A., Voronina E.S., Treshalina H.M., Lushnikova A.A., Tsyganova I.V., Mazurenko N.N.
Human skin melanoma cell lines collection.
(In book chapter) Management of malignant melanoma; None X. (eds.); pp.6.1-6.6; SM Group; Dover; USA (2016)

PubMed=28881731; DOI=10.18632/oncotarget.17014; PMCID=PMC5581030
Emelyanova M., Ghukasyan L., Abramov I., Ryabaya O., Stepanova E.V., Kudryavtseva A., Sadritdinova A., Dzhumakova C., Belysheva T., Surzhikov S., Lyubchenko L., Zasedatelev A., Nasedkina T.
Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.
Oncotarget 8:52304-52320(2017)

PubMed=30551515; DOI=10.1016/j.biopha.2018.11.109
Ryabaya O., Prokofieva A., Akasov R., Khochenkov D., Emelyanova M., Burov S., Markvicheva E., Inshakov A.N., Stepanova E.V.
Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells.
Biomed. Pharmacother. 109:2548-2560(2019)